Jefferies analyst Hisae Kawamoto upgraded Rohto Pharmaceutical (RPHCF) to Buy from Hold with a price target of 2,980 yen, up from 2,200 yen. While Japan sales growth is in the mid-single digits, the underlying resilience of Asia’s performance is “likely to be appreciated,” the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPHCF:
- Rohto Pharmaceutical initiated with a Neutral at UBS
- Rohto Pharmaceutical Reports Strong Growth in Latest Earnings
- Rohto Pharmaceutical Acquires OBAGI Trademarks in Japan
- Rohto Pharmaceutical Revises Earnings and Dividend Forecasts Upward
- Rohto Pharmaceutical Reports Strong Financial Growth and Strategic Expansion